Roche extends blood check attain with sweeping new use claims in Sort 2 diabetes, coronary heart assault danger and extra

0
494

Roche wants to show that you can still teach old biomarkers new tricks. The Big Pharma announced five additional uses for two of its major cardiac tests, which could expand the diagnostic reach of hundreds of millions of new patients.

The new use claims, originally introduced in Europe and in countries that accept the CE mark, measure broader types of cardiovascular risk. The aim is to help providers and patients with chronic illnesses manage their hospital care and predict the long-term chances of stroke, heart attack or death.

The first claim concerns globally used biomarker measurements of NT-proBNP, or N-terminal natriuretic peptide per brain, a hormone released into the bloodstream when the heart muscle walls are stretched. High values ​​can be a sign of cardiac dysfunction and the biomarker has been used to diagnose patients with heart failure.

Now Roche says NT-proBNP levels can also be used to precisely identify patients with type 2 diabetes who are more likely to develop cardiovascular disease later in life. Earlier detection can then lead to earlier treatments that prevented more than half of the hospital admissions and deaths in a previous clinical trial.

According to Roche, NT-proBNP can also be used to identify individuals at risk for atrial fibrillation when combined with a one or more lead electrocardiogram. The abnormal heart rhythm significantly increases the likelihood of a stroke in the course of his life.

RELATED: Abbott’s Highly Sensitive Troponin Blood Test for Heart Attack, Approved by the FDA

The second biomarker, troponin, is a gold standard protein measurement used to diagnose heart attacks and damage to the heart muscle.

According to Roche, using a highly sensitive test, troponin T levels can help provide an early warning system for patients who may develop serious heart conditions, including heart attacks, after surgery elsewhere in the body. The company estimates that of the 200 million people who do not receive cardiac treatment each year, more than 10 million will experience stroke, heart attack, or cardiovascular death in the next 30 days.

Roche also claims the biomarker can help emergency rooms and intensive care units decide when to discharge patients early after suffering from acute coronary syndrome. It is also designed to help fully assess a person’s long-term risks for heart failure, heart attack, and stroke, even though there are no symptoms.

RELATED: Researchers Plan to Create a Saliva-Based Heart Attack Test Following Positive Study Results

Both tests are carried out on the Elecsys test platform and the Cobas e-analyzers from Roche. Over the past three years, highly sensitive troponin tests have been proposed by Siemens and Abbott, the latter showing that elevated levels can predict the likelihood of heart disease in years to come, according to data from a decades-long study.

The new uses of the tests have been approved in Europe and will be immediately available if the company grants regulatory approvals in other countries, according to a Roche press release.